CClinicalTrials.gg
CompletedNCT03550066PEPUpdated Apr 27, 2023Results posted

Patients Engaged in Prevention: Enhancing Outreach to Increase Patient Engagement in Diabetes Prevention

An interventional study of Values affirmation and No affirmation in Preventive Health Services and Health Communication, sponsored by Kaiser Permanente. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-27.

Sponsored by Kaiser Permanente · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This study examines whether a health message that includes a self-affirmation intervention (where people reflect on values that are important to them) increases acceptance of the message and encourages people to take steps to prevent diabetes, as compared to a health message without the self affirmation intervention.

Read the detailed description

Background: Despite availability of evidence-based programs for diabetes prevention, few strategies exist to promote patients' interest in them. Strategies should be developed for racial/ethnic minority women with a history of gestational diabetes (GDM), who face exceptionally high risk for chronic diabetes. We previously found that a theory-based outreach message containing a streamlined values affirmation-two sentences prompting individuals to reflect on core personal values-increased women's likelihood of demonstrating interest in a preventive program. Extending this work, this pilot trial tests whether the values affirmation outreach message is as acceptable as (non-inferior to) a standard outreach message among African-American and Latina women.

Methods: Two-arm, parallel-group, randomized trial among English- and Spanish-speaking minority women with prior GDM and overweight/obesity in a healthcare system. Within an online survey, participants are randomized to read an outreach message promoting an existing preventive program. The message contains either a values affirmation (intervention condition) or no affirmation (control condition).

02

Conditions studied

  • Preventive Health Services
  • Health Communication

Browse trials for

Keywords

  • Diabetes, gestational
  • Diabetes Mellitus
03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's enrollment of 90 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Kaiser Permanente is the lead sponsor of 385 studies on the registry; 41 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • History of gestational diabetes
  • Body mass index ≥25 kg/m2
  • English or Spanish language

Exclusion criteria

Exclusion Criteria:

  • Current diabetes
  • Current pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Values affirmation

    In the values affirmation condition, the health outreach message contained a prompt asking participants to reflect on important personal values.

    Behavioral: Values affirmation

  • Active comparator
    No affirmation

    In the "no affirmation" condition, the health outreach message appeared alone, with no values affirmation.

    Behavioral: No affirmation

Interventions

  • BehavioralValues affirmation

    A health message with a prompt asking participants to reflect on important personal values

  • BehavioralNo affirmation

    A health message alone

06

What researchers measure

Primary outcomes

  1. Acceptance of Health Message

    Index of message acceptance: Persuasiveness (rated on a 7-point scale from not at all (1) to very (7), with higher mean scores corresponding to greater persuasiveness)

    Time frame: Up to 2 weeks

Secondary outcomes

  1. Diabetes Prevention Behavior: Information Seeking

    Seeking information about prevention

    Time frame: Up to 2 weeks

  2. Diabetes Prevention Behavior: Intention

    Behavioral intention to engage in, or seeking information about preventive health services

    Time frame: Up to 2 weeks

07

Results

Posted Aug 20, 2019

Participant flow

Participant flow — Overall Study
MilestoneValues AffirmationNo Affirmation
Started4941
Completed4941
Not completed00

Outcome measures

PrimaryAcceptance of Health Message

Index of message acceptance: Persuasiveness (rated on a 7-point scale from not at all (1) to very (7), with higher mean scores corresponding to greater persuasiveness)

Time frame:
Up to 2 weeks
Reported as:
Mean · units on a scale
Acceptance of Health Message
units on a scaleValues AffirmationNo Affirmation
Acceptance of Health Message5.5 ± 0.95.4 ± 1.2
Statistical analysis
  • Values Affirmation vs No Affirmation · t-test, 2 sided · p = 0.18 (Threshold for statistical significance: \<.05)
SecondaryDiabetes Prevention Behavior: Information Seeking

Seeking information about prevention

Time frame:
Up to 2 weeks
Reported as:
Count of participants · Participants
Diabetes Prevention Behavior: Information Seeking
ParticipantsValues AffirmationNo Affirmation
Diabetes Prevention Behavior: Information Seeking3030
SecondaryDiabetes Prevention Behavior: Intention

Behavioral intention to engage in, or seeking information about preventive health services

Time frame:
Up to 2 weeks
Reported as:
Count of participants · Participants
Diabetes Prevention Behavior: Intention
ParticipantsValues AffirmationNo Affirmation
Diabetes Prevention Behavior: Intention3234

Adverse events

Collected over 1 month. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Values Affirmation0/49 (0%)0/49 (0%)0/49 (0%)
No Affirmation0/41 (0%)0/41 (0%)0/41 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Values AffirmationNo AffirmationTotal
<=18 years000
Between 18 and 65 years494190
>=65 years000
Age, Continuous
Age, Continuous(years)Values AffirmationNo AffirmationTotal
Mean36.3 ± 5.537.0 ± 5.236.5 ± 5.3
Sex: Female, Male
Sex: Female, Male(Participants)Values AffirmationNo AffirmationTotal
Female494190
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Values AffirmationNo AffirmationTotal
Race/Ethnicity — Non-Hispanic Black/African American111324
Race/Ethnicity — Hispanic/Latina362662
Race/Ethnicity — More than one race/ethnicity213
Race/Ethnicity — Not reported011
Region of Enrollment
Region of Enrollment(participants)Values AffirmationNo AffirmationTotal
United States494190
08

Study locations

1 site
  • Kaiser Permanente Northern California
    Oakland, California 94612, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Aug 29, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03550066
Lead sponsor
Kaiser Permanente
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Responsible party
Sponsor
First posted
Jun 8, 2018
Start date
Jun 1, 2018
Primary completion
Jul 3, 2018
Completion
Jul 3, 2018
Results posted
Aug 20, 2019
Last update
Apr 27, 2023

Study contacts

Susan D Brown, PhD
principal investigator · Kaiser Permanente

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion